Novavax to Participate in Upcoming Investor Conferences
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
GAITHERSBURG, Md., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will participate in five upcoming investor conferences. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373.
Conference details are as follows:
Citi 15th Annual BioPharma Virtual Conference
Date: | September 10, 2020 |
Event: | Investor meetings only |
H.C. Wainwright 22nd Annual Global Investment Conference
Date: | September 14, 2020 |
Time: | 9:30 a.m. U.S. Eastern Time (ET) |
Event: | Corporate presentation and investor meetings |
Live Webcast: | www.novavax.com, “Investors”/ “Events” |
Cantor Virtual Global Healthcare Conference
Date: | September 15, 2020 |
Time: | 11:20 a.m. U.S. Eastern Time (ET) |
Event: | Fireside chat and investor meetings |
Live Webcast: | www.novavax.com, “Investors”/ “Events” |
Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Date: | September 16, 2020 |
Time: | 12:30 p.m. U.S. Eastern Time (ET) |
Event: | Fireside chat and investor meetings |
Live Webcast: | www.novavax.com, “Investors”/ “Events” |
Leerink CyberRx Series: Vaccine Forum
Date: | September 23, 2020 |
Time: | 9:00 a.m. U.S. Eastern Time (ET) |
Event: | Fireside chat |
A replay of the presentations will also be accessible under the “Investors/Events” section www.novavax.com.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Silvia Taylor and Erika Trahan
[email protected]
240-268-2022
Media
Brandzone/KOGS Communication
Edna Kaplan
[email protected]
617-974-8659
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AgencyBloc and Ideon Partner to Enhance the Benefits Quoting Experience for Agencies
- Introducing Dunk Tapper, a New Mobile Basketball Challenge from Digital Project Developer DigiNeat LLC
- Purchase of Own Securities and Total Voting Rights
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Citi, Morgan Stanley, Twitter, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!